RadNet Joins Partnership to Explore Potential Alzheimer's Disease Drug

RadNet Joins Partnership to Explore Potential Alzheimer's Disease Drug

RadNet, Eisai and GE Healthcare to Work Together to Evaluate E2609, a BACE
inhibitor, for the Potential Treatment of Alzheimer's Disease

LOS ANGELES and BALTIMORE, July 16, 2013 (GLOBE NEWSWIRE) -- RadNet Inc.
(Nasdaq:RDNT), a national leader in providing high-quality, cost-effective,
fixed-site outpatient diagnostic imaging services through a network of 248
subsidiary-owned and/or operated outpatient imaging centers, announced its
participation in a clinical trial to evaluate the biomarker effects of the
investigational drug E2609, a BACE inhibitor, which is being developed for the
potential disease modifying treatment of Alzheimer's disease (AD). Multiple
RadNet imaging centers will provide the MRI and beta-amyloid positron emission
tomography - computed tomography (PET/CT) capabilities for the clinical trial.
The sites are located in Los Angeles and Baltimore.

The Phase 1 trial will explore whether E2609, a BACE (beta-site amyloid
precursor protein-cleaving enzyme) inhibitor, discovered and developed by
Eisai Co., Ltd., changes the levels of beta-amyloid in patients identified as
having subjective memory complaints and mild cognitive impairment or mild
dementia due to Alzheimer's disease.

The accumulation of beta amyloid in the brain is believed to play a role in
the degeneration of neurons and is one of several pathological characteristics
implicated in the development of Alzheimer's disease. The clinical trial will
use [^18F] Flutemetamol, an investigational PET amyloid imaging agent
developed by GE Healthcare to help select patients for the Phase 1 trial.

"RadNet welcomes the opportunity to join industry leaders and explore the
potential for new technology to help patients suffering from AD," said RadNet
President and CEO Howard Berger, M.D. "Advanced imaging diagnostics not only
has the potential to help physicians select better courses of treatments for
their patients – it enables researchers to secure better trial studies to
develop the next generation of evidence-based treatment."

About RadNet, Inc.

RadNet, Inc. is a national leader in providing high-quality, cost-effective,
fixed-site outpatient diagnostic imaging services through a network of 248
subsidiary-owned and/or operated outpatient imaging centers (inclusive of 23
facilities held in joint ventures). RadNet's core markets include California,
Delaware, Maryland, Rhode Island, New Jersey and New York. Together with
affiliated radiologists, and inclusive of full-time and per diem employees and
technologists, RadNet has a total of approximately 6,300 employees. For more
information, visit RadNet.com.

CONTACT: Andrew Ausanka-Crues
         PR Manager, RadNet
         (805) 451-0931
         acrues@RadNet.com

RadNet, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.